


# Biomarkers in patients with non-small cell lung cancer (NSCLC)



**Key**

1 – Phase I  
2 – Phase II  
3 – Phase III  
4 – FDA Approved

**Medsafe registered medicines for NSCLC**

\*Pharmac funded medicines for people with NSCLC who meet pre-defined criteria

ALK=anaplastic lymphoma kinase; BRAF=v-raf murine sarcoma viral oncogene homolog B1; EGFR=epidermal growth factor receptor; HER2=human epidermal growth factor receptor 2; KRAS=Kirsten rat sarcoma 2 viral oncogene homolog; MEK1=mitogen-activated protein kinase kinase 1; MET=met proto-oncogene; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PD-L1=programmed death-ligand 1; RET=rearranged during transfection; ROS1=ROS proto-oncogene 1; NTRK1=neurotrophic receptor tyrosine kinase 1. Figure adapted from: Tsao AS et al. Scientific Advances in Lung Cancer. J Thorac Oncol. 2015; 11(5): 613-638. References: Medsafe. Product/Application search. Available from: <https://www.medsafe.govt.nz/regulatory/DbSearch.asp>. Accessed: 9 December 2020. Pharmac. Hospital medicines. Available from: <https://pharmac.govt.nz/> Accessed 9 December 2020. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Available from: <https://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed 9 December 2020. ClinicalTrials.gov. Find a study. Available from: <https://www.clinicaltrials.gov/>. Accessed 9 December 2020.

**MEK1**

- Trametinib<sup>2</sup>
- Selumetinib<sup>3</sup>
- Cobimetinib<sup>1</sup>

**PIK3CA**

- LY3023414<sup>2</sup>
- Bimiralisib<sup>1</sup>
- Gedatolisib<sup>2</sup>
- Buparlisib<sup>2</sup>